2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
J

ASCO 2020 H&N Cancers Update: Post-Operative CRT in High-Risk Patients with SCC - What Is the Optimal Dose of Cisplatin? When Should We Use IO vs. Chemo/Cetuximab?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Jochen Lorch
By 2020 ASCO Virtual Direct™ Highlights FEATURING Jochen Lorch
11 views
September 17, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Head&Neck
13:07
2020 ASCO Virtual Direct™ Highlights

ASCO 2020 H&N Cancers Update: Post-Operative CRT in High-Risk Pa…

Feat. J. Lorch
10:13
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Thyroid Cancers: Can the Addition of Pembro Incr…

Feat. J. Lorch
06:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid…

Feat. J. Lorch